Imitrex
Developed to alleviate migraine symptoms and intended to support patient comfort.
Strengths: 25 · 50 · 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Imigran
- Therapeutic class
5-HT1 Receptor Agonist
- Pharmacological class
Triptan
- Precautions and warnings
use with caution in patients with history of seizures; may cause drowsiness
- Minor side effects
nausea; dizziness; fatigue
- Moderate side effects
tingling; hot flush; chest tightness
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
GSK
- Onset Time
30–60 minutes
- Duration
4–6 hours
- Storage instructions
Store below 30°C, away from light.
- Drug interactions
ergotamine; MAO inhibitors; SSRIs
- Age restrictions
Not recommended for children.
- Pregnancy and breastfeeding
Use only if necessary and under medical supervision.
Contraindications
history of myocardial infarction; uncontrolled hypertension; concurrent use of ergotamine derivatives
Serious side effects
arrhythmia — requires immediate medical attention; angina pectoris — requires immediate medical attention
Patient summary
Developed to alleviate migraine symptoms and intended to support patient comfort.
Mechanism of action
Sumatriptan acts as a selective 5-HT1 receptor agonist, causing vasoconstriction of intracranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides.
Imitrex
Developed to alleviate migraine symptoms and intended to support patient comfort.
Editorial Notes
- Active ingredient(s): Sumatriptan
- Listed indication(s): Migraine, Cluster Headache
Usually available as
- 30 tablets - 25 mg373-25-mg-3189
- 10 tablets - 50 mg373-50-mg-3193
- 10 tablets - 100 mg373-100-mg-1175